INVESTOR NOTICE

Interim FY2026 Financial Statements Available

BreastScreening-AI has published an interim financial statement access copy for the period ended 28 February 2026, based on the available interim accounting records.

REPORTING PERIOD	Period ended 28 February 2026
PUBLICATION DATE	15 June 2026
RELATED DOCUMENT	Interim Financial Statements 2026
CURRENCY	Euro (EUR)

EUR 7,476.39 Total assets	**EUR 258.30** Cash and deposits	**EUR -1,064.88** Equity
EUR 8,541.27 Liabilities	**EUR 7,866.32** Supplier liabilities	**EUR -4,575.68** Interim net result

Detailed Announcement

- The access copy summarizes the financial position and income statement for the interim period ended 28 February 2026.
- At the reporting date, total assets were EUR 7,476.39, cash and deposits were EUR 258.30, equity was EUR -1,064.88, and liabilities were EUR 8,541.27.
- Supplier liabilities were EUR 7,866.32. The interim income statement recorded EUR 1,372.42 in external services, EUR 2,624.44 in personnel expenses, and a net result of EUR -4,575.68.
- The interim result has not been annualized and does not incorporate later funding or cash events unless they are recorded in a subsequent accounting period.

Investor Relevance

The interim statement is material to liquidity and working-capital diligence. Low cash, negative equity, and supplier liabilities at the reporting date make funding timing and cash controls important areas for continued review.

Source Basis

- Interim balance sheet and income statement records for the period ended 28 February 2026.

Information Not Established

- The reviewed source set does not establish subsequent cash receipts, investor proceeds, customer collections, a final EIC payment schedule, or a full-year FY2026 forecast.